About our project

The problem we solve: Covid is a major pandemic and effective treatment is required

About our solution: 2 of the three molecules are already proven in invitro test. We have added one more off patent drug in the formulation. The topical application is easy and effective. The plant based alkaloid inhibits viral replication along with being anti-inflammatory and off patent drugs acts on various pathways.

Progress to date:

Formulation ready to be tested invitro at CCMB Hyderabad for Covid.

About Our Company

Innovation Details

Intellectual Property Summary

Provisional patent is filed in India and accepted.

Clinical Information

Cepharanthine and Ivermectin have proven effective in viral reduction invitro. Based on Ivermectin similar class of drug should enhance the combination and topical application makes easier regulatory approval.  

Regulatory Status

Formulation currently in queue for invitro testing for Covid in CCMB India. 

How we will use the funds raised

I plan to outsource entire clinical phase to a reliable firm and seeks emergency FDA approval. FDA approval would be easier on account proven safety of off patent drugs and topical application.

Thank You

This can formulation can be a effective in treating covid hence support us in this initiative

Investor Info

Market Size

TAM - 169,736,766 recovered patient &

Unestimated preventive market for mild and moderate cases

Projected 3 Year Growth

Estimated revenue in 3 years $15 million

Revenue Model

Sustainable revenue model by exclusive sales of product globally

Competitors

Vaccine makers and any other new treatments 

Traction

Center for molecular Biology agreed to test our formulation invitro for Covid based on the molecules profile.

Due Diligence Docs

Please note that access to the company's confidential materials is limited. Click this button to request access from the Company and its representatives.

Send access request

Supporters

There are not supporters yet.

Comments

Updates

No updates found .